Infectious Diseases

Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed under Research and Markets’ Infectious Diseases category.

Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.

For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices. Show Less ... more

• Vaccine Media Monitor

  EURO€ 1,842.00USD$ 2,397.00GBP£ 1,550.00AUD$ 2,344.00JPY¥ 236,645.00SEK 15 737,00CHF 2'259.00CAD$ 2,442.00 Moreover Technologies, May 2013
  About the service: When vaccine news breaks, we get it fast—so you can deliver fresh business intelligence - Search 33,500 news sources - Plus, search 508,000 social media sources - Covers 200 countries...

• Infectious Disease Media Monitor

  EURO€ 1,842.00USD$ 2,397.00GBP£ 1,550.00AUD$ 2,344.00JPY¥ 236,645.00SEK 15 737,00CHF 2'259.00CAD$ 2,442.00 Moreover Technologies, May 2013
  About the service: When infectious disease news breaks, we get it fast—so you can deliver fresh business intelligence - Search 33,500 news sources - Plus, search 508,000 social media sources - Covers...

• Disease & Therapy Review (DTR) Executive Market Summaries

  EURO€ 3,745.00USD$ 3,500.00GBP£ 2,128.00AUD$ 5,095.00JPY¥ 429,472.00SEK 30 202,00CHF 5'027.00CAD$ 4,678.00 Timely Data Resources, Inc, May 2013
  Disease & Therapy Review is meant to be an accurate and efficient executive synopsis of the indications that IPD users look up most frequently Each report includes epidemiology from the IPD (Incidence...

• Daily Updates: Infectious Diseases - Tracking breaking research, drug development news new trials

  EURO€ 88.00USD$ 82.00GBP£ 50.00AUD$ 120.00JPY¥ 10,092.00SEK 710,00CHF 118.00CAD$ 110.00 Lead Discovery, May 2013
  DailyUpdates was launched in 2002 by the pharmaceutical analysts Lead Discovery to provide the R&D sector with a unique intelligence tool We use proprietary search engine technology to identify breaking...

• Pulmonary Tuberculosis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 45
  Pulmonary Tuberculosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Enterococcus Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 106
  Enterococcus Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Enterococcus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Influenza B Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 39
  Influenza B Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Influenza B Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Enterobacteriaceae Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 154
  Enterobacteriaceae Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Enterobacteriaceae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

• Influenza A And B Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 47
  Influenza A And B Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Influenza A And B Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

• Streptococcus Pneumoniae Infection - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 48
  Streptococcus Pneumoniae Infection – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Streptococcus Pneumoniae Infection - Pipeline Review, H2 2013', provides an overview of the indication’s...

• Meningococcal Meningitis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 48
  Meningococcal Meningitis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Meningococcal Meningitis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Streptococcal Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 411
  Streptococcal Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Streptococcal Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 42
  Athlete's Foot (Tinea Pedis) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 39
  Chagas Disease (American Trypanosomiasis) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2013', provides an overview of...

• H3N2 Infection - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 46
  'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for H3N2 Infection, complete...

• Rabies - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 63
  Rabies – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Rabies - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Gram-Positive Bacterial Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 291
  Gram-Positive Bacterial Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Escherichia Coli Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 97
  Escherichia Coli Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Escherichia Coli Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Sepsis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 127
  Sepsis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sepsis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Mar 2013 , Pages: 36
  EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022 Dermatophytic onychomycosis (DO) is an infection of the nail fold or nail plate with dermatophytes, a type of fungus, especially...

• EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Mar 2013 , Pages: 58
  EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV) HCV is an escalating public health problem...

• Dermatomycoses Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 95
  Dermatomycoses Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Dermatomycoses Global Clinical Trials Review, H1, 2013" provides data on the Dermatomycoses clinical trial...

• Cholera Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 60
  Cholera Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Cholera Global Clinical Trials Review, H1, 2013" provides data on the Cholera clinical trial scenario. This report...

• Trypanosomiasis Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 92
  Trypanosomiasis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Trypanosomiasis Global Clinical Trials Review, H1, 2013" provides data on the Trypanosomiasis clinical trial...

• Herpes Simplex Infections Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 108
  Herpes Simplex Infections Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Herpes Simplex Infections Global Clinical Trials Review, H1, 2013" provides data on the Herpes...

• Gonorrhea Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 90
  Gonorrhea Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Gonorrhea Global Clinical Trials Review, H1, 2013" provides data on the Gonorrhea clinical trial scenario. This...

• Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 88
  Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013" provides data on the Leishmaniasis...

• PharmaFocus: Vaccine Adjuvants in Infectious Disease

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Mar 2013 , Pages: 87
  PharmaFocus: Vaccine Adjuvants in Infectious Disease Summary Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry’s “dirty little secret”. Today,...

• Cryptococcosis Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 57
  Cryptococcosis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Cryptococcosis Global Clinical Trials Review, H1, 2013" provides data on the Cryptococcosis clinical trial...

• Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 117
  Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2013" provides data on the Herpes Zoster...

• Impetigo Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Mar 2013 , Pages: 83
  Impetigo Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Impetigo Global Clinical Trials Review, H1, 2013" provides data on the Impetigo clinical trial scenario. This report...

• Influenza - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 459
  Influenza – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Influenza - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Typhoid Fever - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 42
  Typhoid Fever – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Typhoid Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Klebsiella Pneumoniae Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 46
  Klebsiella Pneumoniae Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Klebsiella Pneumoniae Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Bacterial Pneumonia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 71
  Bacterial Pneumonia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Bacterial Pneumonia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 253
  Mycobacterium Tuberculosis Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Cholera - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 41
  Cholera – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cholera - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Abscess - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 47
  Abscess – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Abscess - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 53
  Leishmaniasis (Kala-Azar) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Nosocomial Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 87
  Nosocomial Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Yellow Fever - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 44
  Yellow Fever – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Yellow Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 53
  Meningococcemia (Meningococcal Infections) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Meningococcemia (Meningococcal Infections) - Pipeline Review, H1 2013', provides an overview...

• African Trypanosomiasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 39
  African Trypanosomiasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'African Trypanosomiasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Complicated Intra-Abdominal Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 56
  Complicated Intra-Abdominal Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Complicated Intra-Abdominal Infections - Pipeline Review, H1 2013', provides an overview of the...

• When Culture Impacts Health

  EURO€ 54.00USD$ 70.00GBP£ 45.00AUD$ 69.00JPY¥ 6,930.00SEK 461,00CHF 66.00CAD$ 72.00 Elsevier Science and Technology, Mar 2013 , Pages: 380
  Bringing the hard-to-quantify aspects of lived experience to analysis, and emphasizing what might be lost in interventions if cultural insights are absent, this book includes case studies from across...

• Infection Control Market - Sterilization & Disinfection – Global forecast to 2017

  EURO€ 3,574.00USD$ 4,650.00GBP£ 3,007.00AUD$ 4,548.00JPY¥ 459,108.00SEK 30 531,00CHF 4'383.00CAD$ 4,738.00 Markets and Markets, Mar 2013 , Pages: 356
  Infection Control Market [Sterilization (EtO Sterilization, E-Beam, Gamma, Steam, Low Temperature & Contract Services) & Disinfection (Endoscope Reprocessing, Disinfectant, Disinfector, Face Mask, Drapes,...

• Smallpox - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 92
  Smallpox – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Smallpox - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Actinic Keratosis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 60
  Actinic Keratosis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Actinic Keratosis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Pertussis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 70
  Pertussis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Pertussis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Relapsed Multiple Myeloma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 222
  Relapsed Multiple Myeloma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Relapsed Multiple Myeloma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....